News
ELTX
14.85
+6.53%
0.91
Elicio Therapeutics Price Target Announced at $27.00/Share by B. Riley Securities
Dow Jones · 2d ago
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27
Benzinga · 2d ago
Elicio Therapeutics initiated with a Buy at B. Riley
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle
Reuters · 3d ago
ELICIO THERAPEUTICS INC <ELTX.O>: B. RILEY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $27
Reuters · 3d ago
Weekly Report: what happened at ELTX last week (0601-0605)?
Weekly Report · 5d ago
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
TipRanks · 06/01 14:06
Elicio Therapeutics Announces Publication Of Peer-Reviewed Manuscript In Science Advances Describing Novel AMP-DNA Adjuvant Candidates
Benzinga · 06/01 12:07
Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses
PUBT · 06/01 12:01
Weekly Report: what happened at ELTX last week (0525-0529)?
Weekly Report · 06/01 09:59
Largest borrow rate increases among liquid names
TipRanks · 05/28 15:27
Burns Reiterates Buy on ELI‑002 Program, Maintains $17 Price Target Amid Encouraging Early Efficacy Signals
TipRanks · 05/28 10:26
Largest borrow rate increases among liquid names
TipRanks · 05/27 13:23
Weekly Report: what happened at ELTX last week (0518-0522)?
Weekly Report · 05/25 10:02
Largest borrow rate increases among liquid names
TipRanks · 05/21 12:45
Weekly Report: what happened at ELTX last week (0511-0515)?
Weekly Report · 05/18 10:02
Boris Peaker Initiates Buy on Elicio Therapeutics, Citing Promising Phase 2b ELI-002 7P Data and Setting $18 Price Target
TipRanks · 05/12 20:35
Elicio Therapeutics GAAP EPS of -$0.65 misses by $0.18
Seeking Alpha · 05/11 20:58
Elicio Therapeutics Q1 net loss widens, cash runway extends into Q4 2026
Reuters · 05/11 20:16
Elicio Therapeutics Q1 FY26 net loss widens to $11.8 million; loss per share narrows to $0.65
PUBT · 05/11 20:07
More
Webull provides a variety of real-time ELTX stock news. You can receive the latest news about Elicio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.